← Ticker index
EW
Ticker
EW
Congressional Trades
44
by 8 members
Ticker disclosure brief
Congressional disclosure records for EW
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-05-27
Largest range
$50K – $100K
Jefferson Shreve
Longest observed gap
147d
Tommy Tuberville
Highest 30d vs SPY
14.0%
Ro Khanna
Purchase rows
20
45%
Sale rows
24
55%
Disclosed midpoint
$602K
range estimate
Unique Traders
8
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats25 · 57%
Republicans19 · 43%
Federal awards
all →- 2026-07-10$34KDepartment of Veterans AffairsTAVR
- 2026-07-10$34KDepartment of Veterans AffairsHEART VALVE
- 2026-07-10$16KDepartment of Veterans AffairsAORTIC VALVE
- 2026-07-09$36KDepartment of Veterans AffairsEVOQUE HEART VALVE
- 2026-07-09$34KDepartment of Veterans AffairsHEART VALVE
- 2026-07-09$34KDepartment of Veterans AffairsINVENTORY ITEM
- 2026-07-08$34KDepartment of Veterans AffairsHEART VALVE
- 2026-07-08$24KDepartment of Veterans AffairsEMERGENCY EDWARDS HEMOSPHERE MODULES PMI
- 2026-07-07$34KDepartment of Veterans AffairsPROSTHETICS EMERGENCY HEART VALVE IMPLANT
- 2026-07-07$34KDepartment of Veterans AffairsVALVE
Lobbying filings
all →- 2026-06-29$0EDWARDS LIFESCIENCES LLCTrade policy and tariffs.
- 2026-04-20$340KEDWARDS LIFESCIENCES LLCEnsuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development Tariffs
- 2026-04-20$50KEDWARDS LIFESCIENCES LLCCoverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0
- 2026-04-20$50KEDWARDS LIFESCIENCES LLCProvide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
- 2026-04-20$50KEDWARDS LIFESCIENCES LLCMedicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process
- 2026-01-20$350KEDWARDS LIFESCIENCES LLCEnsuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Japan Reimbursement of Medical Devices
- 2026-01-20$50KEDWARDS LIFESCIENCES LLCProvide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue
- 2026-01-20$50KEDWARDS LIFESCIENCES LLCCoverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0
- 2026-01-20$50KEDWARDS LIFESCIENCES LLCMedicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders
- 2025-10-20$280KEDWARDS LIFESCIENCES LLCCorporate Tax Reform Proposals Tariffs Japan Reimbursement of Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development
Loading trade analytics…
All Disclosed Trades
Page 2 · 19 of 44 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2025-04-08 | RRobert Bresnahan | BUY | $1K – $15K | 30d | receipt → |
| 2025-04-07 | RJefferson Shreve | BUY | $15K – $50K | 31d | receipt → |
| 2025-04-08 | RRobert Bresnahan | BUY | $1K – $15K | 30d | receipt → |
| 2025-04-07 | RJefferson Shreve | BUY | $15K – $50K | 31d | receipt → |
| 2025-03-03 | RBruce Westerman | BUY | $1K – $15K | 44d | receipt → |
| 2025-03-03 | RBruce Westerman | BUY | $1K – $15K | 44d | receipt → |
| 2025-03-12 | DRo Khanna | BUY | $1K – $15K | 29d | receipt → |
| 2025-03-12 | DRo Khanna | BUY | $1K – $15K | 29d | receipt → |
| 2024-11-12 | DRo Khanna | BUY | $1K – $15K | 23d | receipt → |
| 2024-11-12 | DRo Khanna | BUY | $1K – $15K | 23d | receipt → |
| 2024-08-02 | DRo Khanna | SELL | $1K – $15K | 35d | receipt → |
| 2024-08-02 | DRo Khanna | SELL | $1K – $15K | 35d | receipt → |
| 2024-04-11 | RMike Kelly | SELL | $1K – $15K | 64dApparent delay | receipt → |
| 2024-04-11 | RMike Kelly | SELL | $1K – $15K | 64dApparent delay | receipt → |
| 2024-04-11 | RMike Kelly | SELL | $1K – $15K | 34d | receipt → |
| 2023-04-03 | RTommy Tuberville | SELL | $1K – $15K | 147dApparent delay | receipt → |
| 2021-03-29 | RTommy Tuberville | BUY | $1K – $15K | 882dApparent delay | receipt → |
| 2023-06-21 | RJohn Curtis | BUY | $1K – $15K | 26d | receipt → |
| 2023-04-26 | RJohn Curtis | BUY | $1K – $15K | 6d | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.